Fistula News and Research

RSS

A Fistula is an abnormal opening or passage between two organs or between an organ and the surface of the body. Fistulas may be caused by injury, infection, or inflammation, or may be created during surgery.

Study finds link between Medicaid expansion and lower death rates among dialysis patients

In the first three years of Medicaid expansion due to the Affordable Care Act, the number of patients with end-stage kidney disease who died within a year of starting dialysis decreased in states that expanded Medicaid compared to non-expansion states, new research found.

25 Oct 2018

New approach using 'cellular dust' offers hope for regenerative medicine

While stem cells have the most therapeutic potential, the benefits of regenerative medicine may best be mobilized using extracellular vesicles (EVs), also known in the past as "cellular dust".

24 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

FDA grants marketing authorization for use of two catheter-based devices in hemodialysis patients

Today, the U.S. Food and Drug Administration permitted marketing of two catheter-based devices designed to create a connection to veins and arteries in patients with chronic kidney disease who need hemodialysis.

22 Jun 2018

New tool gives hope for women with fistula injuries

The health care systems in the United States and other industrialized countries have outgrown many of the childbirth-related injuries that are still very problematic in poor countries.

21 May 2018

FDA authorizes marketing of Hemospray device for treating GI bleeding

Today, the U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.

8 May 2018

Opioid pain medications may not be safe for hemodialysis patients

A new analysis indicates that opioid pain medications may not be as safe for hemodialysis patients as recommendations suggest, and therefore, their use should be limited when possible. The analysis appears in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

20 Apr 2018

Researchers discover link between hypothyroidism and wound healing complications

Researchers at the University of Michigan have discovered a link between low thyroid hormone levels and wound healing complications.

7 Mar 2018

Study highlights risks involved in short-term use of PICCs

Many hospital patients get medicine or nutrition delivered straight into their bloodstream through a tiny device called a PICC. In just a decade, it's become the go-to device for intravenous care.

24 Feb 2018

New biomarker may indicate success of popular treatment for atrial fibrillation

Johns Hopkins researchers report successful use of heart imaging to predict the benefit or futility of catheter ablation, an increasingly popular way to treat atrial fibrillation, a common heart rhythm disorder.

12 Feb 2018

Report highlights risk of severe injuries caused by swallowed button batteries from 'fidget spinners'

A report of two young children with burns of the esophagus caused by swallowed button batteries from "fidget spinners" highlights a risk of severe injuries involving these popular toys, according to a series of reports in the January/February Journal of Pediatric Gastroenterology and Nutrition.

27 Jan 2018

First-of-its-kind nonsynthetic, decellularized graft one step closer to clinical trials

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doesn't contain any living cells at implantation. The vessel, that could be used as an "off the shelf" graft for kidney dialysis patients, performed well in a recent study with nonhuman primates.

1 Nov 2017

Report: Overall burden of kidney disease remains high in the U.S.

According to an annual data report from the United State Renal Data System, the overall burden of kidney disease remains high in U.S. with the rates of kidney failure requiring dialysis or kidney transplantation ranking among the highest in the world.

26 Oct 2017

Fistula News and Research

Further Reading

Study finds link between Medicaid expansion and lower death rates among dialysis patients

New approach using 'cellular dust' offers hope for regenerative medicine

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

FDA grants marketing authorization for use of two catheter-based devices in hemodialysis patients

New tool gives hope for women with fistula injuries

FDA authorizes marketing of Hemospray device for treating GI bleeding

Opioid pain medications may not be safe for hemodialysis patients

Researchers discover link between hypothyroidism and wound healing complications

Study highlights risks involved in short-term use of PICCs

New biomarker may indicate success of popular treatment for atrial fibrillation

Report highlights risk of severe injuries caused by swallowed button batteries from 'fidget spinners'

First-of-its-kind nonsynthetic, decellularized graft one step closer to clinical trials

Report: Overall burden of kidney disease remains high in the U.S.

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News